Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment

07/16/2014 | 08:45pm US/Eastern

By a News Reporter-Staff News Editor at Cancer Weekly -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announced it has entered into an agreement with Merck KGaA, Darmstadt, Germany, which operates as EMD Serono in the United States and Canada, to collaborate with Merck KGaA's biopharmaceutical division on the development and commercialization of a companion diagnostic (CDx) for an undisclosed target using Ventana's proprietary diagnostic assays. In alignment with Merck KGaA's strategic approach in personalized medicine, the aim is to develop a patient stratifying diagnostic test that can be used in multiple cancer indications. Merck KGaA, which is actively investing in innovation in the CDx field through a number of partnerships, will leverage Ventana's global leadership position in cancer diagnostics and vast expertise in CDx to achieve new levels of diagnostic clarity for the investigated target. As part of the agreement, Ventana will develop and validate the CDx and ensure its readiness, availability, and adherence to FDA and other health authority standards for future clinical trials (see also Ventana Medical Systems, Inc.).

"Tailoring therapies based on a patient's specific genes, proteins or tissue environment is a key expansion area for oncology. We are very pleased to partner with Merck in Darmstadt, Germany to co-develop a CDx that will play a vital role in improving the quality of care for cancer patients," said Doug Ward, Vice President, Companion Diagnostics, Ventana Medical Systems, Inc. "Ventana is committed to continuing to provide the industry's gold standard in biomarker detection using our proprietary assays as the basis for novel companion diagnostic tests."

This pharma partnership is one of several currently underway where the Ventana Companion Diagnostics team is delivering patient stratifying diagnostic tests that help identify those patients who are most likely to benefit from specific treatments. In addition to the biopharmaceutical division of Merck KGaA, Ventana has announced partnerships with Bayer, Pfizer, Boehringer Ingelheim, Takeda's Millennium unit, Genmab, Incyte, MedImmune and more. Since 2002, the company has worked with more than 45 biopharmaceutical partners and is currently engaged in more than 180 collaborative projects to develop and commercialize companion diagnostics globally.

Companion diagnostics (CDx) are tests designed to confirm the presence of a specific biomarker to assist physicians in selecting effective therapies for their patients, based on the individual characteristics of each person. Incorporating a companion diagnostic strategy into a drug development program may expedite the drug approval process and help generate more effective treatments with improved safety profiles for patients.

Keywords for this news article include: Cancer, Genetics, Oncology, Ventana Medical Systems Inc.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

(c) 2014 NewsRx LLC

React to this article
Latest news
Date Title
11:23p TOKYO GAS : JX Energy eye doubling output at power plant in Kawasaki
11:22p HYUNDAI HCN : BRIEF: One dead in crossover, head-on collision east of Sandy on US 26; road remains closed
11:20p DYNAMIC MATERIALS : Boulder's Dynamic Materials Corp. to restate 2012, 2013 reports because of accounting errors
11:18p J D WETHERSPOON : BRIEF: UT men fall at Eastern Michigan 85-59
11:16p AGILENT TECHNOLOGIES : How we tested marijuana potency for 15 edible products available in Oregon
11:16p INTEL : baby death: Why autopsy couldn't determine how 6-month-old died after being left in hot car
11:08p GOOGLE 'C' : Fiber raises rates for TV subscriptions for new customers
11:02p YAHOO : CEO stalked by man in Austin, police say
11:02p OREXIGEN THERAPEUTICS : SHAREHOLDER ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Therapeutics, Inc.
10:58p UNITED TECHNOLOGIES : Gardens OKs incentives to bring Fortune 500 HQ to city
Latest news
Advertisement
Hot News 
BELLZONE MINING : Financing Update and Restoration of Trading
SNOOZEBOX : Confirms Ealing Council Project With Mears Group
CHURCHILL MINING : Board Change
THOMAS COOK : Cook and Fosun Strategic Partnership
MTY NV : ASML Receives Intel's Preferred Quality Supplier Award
Most Read News
06:29p CRACKER BARREL OLD COUNTRY STORE : LaVale Cracker Barrel plans moving forward
06:02p CALAVO GROWERS : SECURITIES ALERT: Rosen Law Firm Reminds Calavo Growers Inc. Investors of Important March 23, 2015 Deadline in Class Action
07:07pDJPETROLEO BRASILEIRO PETROBRAS : Brazil Supreme Court Clears Probe of Top Lawmakers Amid Petrobras Scandal
06:06pDJINTUIT : Has Been Contacted by DOJ and FTC
08:31p BARCLAYS : named ‘Best Foreign Investment Bank' in UAE by EMEA Finance
Most recommended articles
10:50p WEEKLY TRADING FORECAST : FX and Capital Markets Shaken by Strong NFPs
10:50pDJBrazil Supreme Court Clears Probe of Lawmakers Amid Petrobras Scandal -- Update
10:45p Dollar Acceleration and S&P 500 Reversal Before FOMC Gathers?
10:14p Bank of Canada head says oil shock looks front-loaded
10:09p Fiat Chrysler recalls 703,000 vehicles in U.S. to fix ignition switches
Dynamic quotes  
ON
| OFF